Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580361444> ?p ?o ?g. }
- W2580361444 endingPage "142" @default.
- W2580361444 startingPage "135" @default.
- W2580361444 abstract "The established clinical staging systems (Rai/Binet) of chronic lymphocytic leukemia (CLL) cannot accurately predict the appropriate treatment of patients in the earlier stages. In the past two decades, several prognostic factors have been identified to predict the outcome of patients with CLL, but only a few studies investigated more markers together. To predict the time to first treatment (TTFT) in patients of early stages, we evaluated the prognostic role of conventional markers as well as cytogenetic abnormalities and combined them together in a new prognostic scoring system, the CLL prognostic index (CLL-PI).Taking advantage of a population of 406 untreated Chinese patients with CLL at early and advanced stage of disease, we identified the strongest prognostic markers of TTFT and, subsequently, in a cohort of 173 patients who had complete data for all 3 variables, we integrated the data of traditional staging system, cytogenetic aberrations, and mutational status of immunoglobulin heavy chain variable region (IGHV) in CLL-PI. The median follow-up time was 45 months and the end point was TTFT.The median TTFT was 38 months and the 5-year overall survival was 80%. According to univariate analysis, patients of advanced Rai stages (P < 0.001) or with 11q- (P = 0.002), 17p- (P < 0.001), unmutated IGHV (P < 0.001), negative 13q- (P = 0.007) and elevated lactate dehydrogenase levels (P = 0.001) tended to have a significantly shorter TTFT. And subsequently, based on multivariate Cox regression analysis, three independent factors for TTFT were identified: advanced clinical stage (P = 0.002), 17p- (P = 0.050) and unmutated IGHV (P = 0.049). Applying weighted grading of these independent factors, a CLL-PI was constructed based on regression parameters, which could categorize four different risk groups (low risk [score 0], intermediate low [score 1], intermediate high [score 2] and high risk [score 3-6]) with significantly different TTFT (median TTFT of not reached (NR), 65.0 months, 36.0 months and 19.0 months, respectively, P < 0.001).This study developed a weighted, integrated CLL-PI prognostic system of CLL patients which combines the critical genetic prognostic markers with traditional clinical stage. This novel modified PI system could be used to discriminate among groups and may help predict the TTFT and prognosis of patients with CLL." @default.
- W2580361444 created "2017-02-03" @default.
- W2580361444 creator A5000632526 @default.
- W2580361444 creator A5001940334 @default.
- W2580361444 creator A5002960038 @default.
- W2580361444 creator A5006292484 @default.
- W2580361444 creator A5007951489 @default.
- W2580361444 creator A5008291441 @default.
- W2580361444 creator A5017214725 @default.
- W2580361444 creator A5027278571 @default.
- W2580361444 creator A5030715375 @default.
- W2580361444 creator A5035740553 @default.
- W2580361444 creator A5065439417 @default.
- W2580361444 creator A5075403741 @default.
- W2580361444 creator A5081850178 @default.
- W2580361444 creator A5086619049 @default.
- W2580361444 date "2017-01-20" @default.
- W2580361444 modified "2023-09-22" @default.
- W2580361444 title "Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia." @default.
- W2580361444 cites W1243376384 @default.
- W2580361444 cites W1429374962 @default.
- W2580361444 cites W1527161131 @default.
- W2580361444 cites W154103547 @default.
- W2580361444 cites W1766897881 @default.
- W2580361444 cites W179476222 @default.
- W2580361444 cites W1876001658 @default.
- W2580361444 cites W1965851569 @default.
- W2580361444 cites W1966122750 @default.
- W2580361444 cites W1979073669 @default.
- W2580361444 cites W1979918288 @default.
- W2580361444 cites W1979921794 @default.
- W2580361444 cites W1993355130 @default.
- W2580361444 cites W1993745533 @default.
- W2580361444 cites W2011572687 @default.
- W2580361444 cites W2026872065 @default.
- W2580361444 cites W2043415097 @default.
- W2580361444 cites W2072266823 @default.
- W2580361444 cites W2075329854 @default.
- W2580361444 cites W2080951919 @default.
- W2580361444 cites W2084952484 @default.
- W2580361444 cites W2086637735 @default.
- W2580361444 cites W2091766432 @default.
- W2580361444 cites W2094252783 @default.
- W2580361444 cites W2099348990 @default.
- W2580361444 cites W2102284860 @default.
- W2580361444 cites W2105921327 @default.
- W2580361444 cites W2132838873 @default.
- W2580361444 cites W2157596388 @default.
- W2580361444 cites W2204433245 @default.
- W2580361444 cites W2318933236 @default.
- W2580361444 doi "https://doi.org/10.4103/0366-6999.197978" @default.
- W2580361444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5282668" @default.
- W2580361444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28091403" @default.
- W2580361444 hasPublicationYear "2017" @default.
- W2580361444 type Work @default.
- W2580361444 sameAs 2580361444 @default.
- W2580361444 citedByCount "5" @default.
- W2580361444 countsByYear W25803614442018 @default.
- W2580361444 countsByYear W25803614442019 @default.
- W2580361444 countsByYear W25803614442020 @default.
- W2580361444 countsByYear W25803614442023 @default.
- W2580361444 crossrefType "journal-article" @default.
- W2580361444 hasAuthorship W2580361444A5000632526 @default.
- W2580361444 hasAuthorship W2580361444A5001940334 @default.
- W2580361444 hasAuthorship W2580361444A5002960038 @default.
- W2580361444 hasAuthorship W2580361444A5006292484 @default.
- W2580361444 hasAuthorship W2580361444A5007951489 @default.
- W2580361444 hasAuthorship W2580361444A5008291441 @default.
- W2580361444 hasAuthorship W2580361444A5017214725 @default.
- W2580361444 hasAuthorship W2580361444A5027278571 @default.
- W2580361444 hasAuthorship W2580361444A5030715375 @default.
- W2580361444 hasAuthorship W2580361444A5035740553 @default.
- W2580361444 hasAuthorship W2580361444A5065439417 @default.
- W2580361444 hasAuthorship W2580361444A5075403741 @default.
- W2580361444 hasAuthorship W2580361444A5081850178 @default.
- W2580361444 hasAuthorship W2580361444A5086619049 @default.
- W2580361444 hasConcept C10515644 @default.
- W2580361444 hasConcept C105795698 @default.
- W2580361444 hasConcept C126322002 @default.
- W2580361444 hasConcept C143998085 @default.
- W2580361444 hasConcept C144301174 @default.
- W2580361444 hasConcept C146357865 @default.
- W2580361444 hasConcept C151730666 @default.
- W2580361444 hasConcept C161584116 @default.
- W2580361444 hasConcept C199163554 @default.
- W2580361444 hasConcept C2777609679 @default.
- W2580361444 hasConcept C2777938653 @default.
- W2580361444 hasConcept C2778461978 @default.
- W2580361444 hasConcept C33923547 @default.
- W2580361444 hasConcept C38180746 @default.
- W2580361444 hasConcept C50382708 @default.
- W2580361444 hasConcept C71924100 @default.
- W2580361444 hasConcept C72563966 @default.
- W2580361444 hasConcept C86803240 @default.
- W2580361444 hasConceptScore W2580361444C10515644 @default.
- W2580361444 hasConceptScore W2580361444C105795698 @default.
- W2580361444 hasConceptScore W2580361444C126322002 @default.
- W2580361444 hasConceptScore W2580361444C143998085 @default.